Cue Biopharma (NASDAQ:CUE - Get Free Report) is projected to release its earnings data on Wednesday, March 26th. Analysts expect Cue Biopharma to post earnings of ($0.15) per share and revenue of $1.70 million for the quarter.
Cue Biopharma Price Performance
Shares of Cue Biopharma stock traded up $0.02 during midday trading on Friday, hitting $0.98. 91,842 shares of the company were exchanged, compared to its average volume of 447,216. The firm has a 50 day simple moving average of $1.25 and a 200-day simple moving average of $1.16. The company has a debt-to-equity ratio of 0.05, a current ratio of 2.22 and a quick ratio of 2.22. The firm has a market cap of $62.37 million, a P/E ratio of -1.09 and a beta of 1.88. Cue Biopharma has a 52 week low of $0.45 and a 52 week high of $2.26.
About Cue Biopharma
(
Get Free Report)
Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer.
Featured Articles
Before you consider Cue Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cue Biopharma wasn't on the list.
While Cue Biopharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
